Skip to main content
. Author manuscript; available in PMC: 2015 Apr 29.
Published in final edited form as: BMB Rep. 2009 Mar 31;42(3):142–147. doi: 10.5483/bmbrep.2009.42.3.142

Fig. 2.

Fig. 2

SB 203580 and SB 202190 are potent inhibitors of CREB Ser-108/111/114 phosphorylation. (A), SB 203580 inhibits CREB Ser-108/111/114 phosphorylation. HEK 293T cells were either mock-treated or pretreated with the p38 inhibitor SB 203580 (10 μM). They were then exposed to CHX (20 μg/ml) or 5 Gy IR or both for a period of 2 h. Cell extracts were immunoblotted with α-CREB, α-pCREB–S108/111/114 and α-pMCM3 antibodies. Note: The α-pMCM3 blot was probed with the α–pCREB-S121 antibody, which crossreacts with the ATM-phosphorylated form of MCM3 (22). Only the 100-kDa region of the membrane containing MCM3 is shown. (B), The JNK inhibitor SP 600125 does not affect CREB Ser108/111/114 phosphorylation. HEK 293T cells were either left untreated or pretreated with the JNK inhibitor SP 600125 (10 μM) or p38 inhibitor SB 202190 (10 μM). The cells were then exposed to CHX (20 μg/ml) for a period of 2 h. Cell extracts were analyzed by immunoblotting with α-CREB and α-pCREB–S108/111/114 antibodies.